Page 306 - Binder
P. 306

Nomination Recognition 2017


        Report by Individual Nominee


       CATEGORY:  GREAT COLLABORATION

       NOMINEE                 NOMINATOR             DEPARTMENT
       Beth Glasgow            David Macinga         Regulatory Affairs 600650


       Describe the situation or event related to the individual's or team's performance.

       This project is a mega-collaboration between several product manufacturers, clinical testing laboratories, study
       monitors, consultants, and the Food and Drug Administration.  Beth tapped into her excellent project
       management skills and her expertise in FDA drug development procedures to ensure that the project
       progressed on track with high quality. She developed robust timelines used an assertive but non-aggressive
       communication style to keep team members within GOJO as well as external collaborators engaged and on
       task to ensure that we met deadlines. She was a facilitator, helping with overall contract negotiations with
       Indian clinical lab to facilitate and the leader of biweekly conference calls between US technical team and
       Indian. She also managed the overall relationship between ACI coalition and study monitors.


       Describe in detail the individual's or team's notable behaviors.
       Beth displays a strong passion to defend alcohol for GOJO?s and the category and has taken personal
       ownership for the success of these efforts.  She also understands the need to collaborate with external
       partners with diverse, and sometimes conflicting motivations and needs.


       What were the results of the individual’s or team’s behaviors?
       Beth served as a project manager, coordinating and managing all internal efforts to support alcohol and
       antimicrobial monograph defense efforts.  She also proactively stepped up to help manage the external
       industry efforts being coordinated through the American Cleaning Institute.  Her efforts were instrumental in
       successfully executing three large efficacy studies, writing and submitting a human safety protocol, executing a
       complex contract with a Clinical Testing Facility in India, and drafting and submitting a compelling briefing
       package to the US FDA.

       CONTRIBUTORS:
       Chris Fricker, Sarah Wilson, Antonio Qui?ones-Rivera, Mike Dolan, Srini Venkatesh, Dave Macinga



























     rptIndividualNomination                                                      Tuesday, February 13, 2018 306
   301   302   303   304   305   306   307   308   309   310   311